Bacteria-free minicircle DNA system to generate integration-free CAR-T cells

Background Chimeric antigen receptor T (CAR-T) cells engineered with lentiviral and retroviral vectors have been successfully applied to treat patients with B cell malignancy. However, viral integration in T cells has the potential risk of mutagenesis, and viral vector production demands effort and is costly. Using non-integrative episomal vector such as minicircle vector to generate integration-free CAR-T cells is an attractive option. Methods and results We established a novel method to generate minicircle vector within a few hours using simple molecular biology techniques. Since no bacteria is involved, we named these vectors bacteria-free (BF) minicircle. In comparison with plasmids, BF minicircle vector enabled higher transgene expression and improved cell viability in human cell line, stem cells and primary T cells. Using BF minicircle vector, we generated integration-free CAR-T cells, which eliminated cancer cells efficiently both in vitro and in vivo. Conclusion BF minicircle vector will be useful in basic research as well as in clinical applications such as CAR-T and gene therapy. Although the transgene expression of minicircle vector lasts apparently shorter than that of insertional lentivirus, multiple rounds of BF minicircle CAR-T cell infusion could eliminate cancer cells efficiently. On the other hand, a relatively shorter CAR-T cell persistence provides an opportunity to avoid serious side effects such as cytokine storm or on-target off-tumour toxicity.

[1]  C. June,et al.  Driving gene-engineered T cell immunotherapy of cancer , 2016, Cell Research.

[2]  H. Einsele,et al.  Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors , 2017, Leukemia.

[3]  C. Orosz,et al.  Gene therapy in transplantation: pathological consequences of unavoidable plasmid contamination with lipopolysaccharide. , 1999, Transplant immunology.

[4]  Jedd D. Wolchok,et al.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.

[5]  M. Kay,et al.  A Simple And Rapid Minicircle DNA Vector Manufacturing System , 2010, Nature Biotechnology.

[6]  M. Kay,et al.  Novel Minicircle Vector for Gene Therapy in Murine Myocardial Infarction , 2009, Circulation.

[7]  Jedd D. Wolchok,et al.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy , 2016, Nature Reviews Clinical Oncology.

[8]  J. Thomson,et al.  Embryonic stem cell lines derived from human blastocysts. , 1998, Science.

[9]  N. Nafissi,et al.  Construction and Characterization of an in-vivo Linear Covalently Closed DNA Vector Production System , 2012, Microbial Cell Factories.

[10]  J. Perrard,et al.  Poly-L-glutamate, an anionic polymer, enhances transgene expression for plasmids delivered by intramuscular injection with in vivo electroporation , 2002, Gene Therapy.

[11]  Chenyang Zhao,et al.  Considerations for Clinical Review of Cellular Therapy Products: Perspectives of the China Food and Drug Administration Center for Drug Evaluation. , 2018, Human Gene Therapy.

[12]  M. Branca Gene therapy: cursed or inching towards credibility? , 2005, Nature Biotechnology.

[13]  M. Kay,et al.  Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  A. Fischer Gene therapy: Myth or reality? , 2016, Comptes rendus biologies.

[15]  D. Porter,et al.  Chimeric antigen receptor T cell therapy: 25years in the making. , 2016, Blood reviews.

[16]  A. Cheng,et al.  CRISPR-Cas9-mediated multiplex gene editing in CAR-T cells , 2016, Cell Research.

[17]  Carl H. June,et al.  Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition , 2016, Clinical Cancer Research.

[18]  CRISPR-Cas 9-mediated multiplex gene editing in CART cells , 2017 .